These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23173582)

  • 1. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression.
    Serafini G; Pompili M; Innamorati M; Dwivedi Y; Brahmachari G; Girardi P
    Curr Pharm Des; 2013; 19(10):1898-922. PubMed ID: 23173582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NMDA receptor as a therapeutic target in major depressive disorder.
    Pittenger C; Sanacora G; Krystal JH
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):101-15. PubMed ID: 17430148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NMDA receptor antagonists for depression: Critical considerations.
    Serafini G; Gonda X; Rihmer Z; Pompili M; Girardi P; Nasrallah HA; Amore M
    Ann Clin Psychiatry; 2015 Aug; 27(3):213-20. PubMed ID: 26247220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression.
    Szakacs R; Janka Z; Kalman J
    Neuropsychopharmacol Hung; 2012 Mar; 14(1):29-40. PubMed ID: 22427468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
    Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
    Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutamate and depression: clinical and preclinical studies.
    Paul IA; Skolnick P
    Ann N Y Acad Sci; 2003 Nov; 1003():250-72. PubMed ID: 14684451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc in the Glutamatergic Theory of Depression.
    Mlyniec K
    Curr Neuropharmacol; 2015; 13(4):505-13. PubMed ID: 26412070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of NMDA receptor in neurobiology and treatment of major depressive disorder: Evidence from translational research.
    Amidfar M; Woelfer M; Réus GZ; Quevedo J; Walter M; Kim YK
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Aug; 94():109668. PubMed ID: 31207274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamatergic Modulators in Depression.
    Henter ID; de Sousa RT; Zarate CA
    Harv Rev Psychiatry; 2018; 26(6):307-319. PubMed ID: 29465478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.
    Huang YJ; Lane HY; Lin CH
    Neural Plast; 2017; 2017():4605971. PubMed ID: 28491480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabotropic glutamate receptors in the control of mood disorders.
    Witkin JM; Marek GJ; Johnson BG; Schoepp DD
    CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of Exploring N-Methyl-D-Aspartate (NMDA) as a Future Perspective Target in Depression.
    Bhatia NY; Ved HS; Kale PP; Doshi GM
    CNS Neurol Disord Drug Targets; 2022; 21(10):1004-1016. PubMed ID: 35352638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of glutamate signaling in preclinical and/or mechanistic models of depression.
    Tokita K; Yamaji T; Hashimoto K
    Pharmacol Biochem Behav; 2012 Feb; 100(4):688-704. PubMed ID: 21536063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Effect of Novel Antidepressant Drugs Acting at Specific Receptors of Neurotransmitters and Neuropeptides.
    Werner FM; Coveñas R
    Curr Pharm Des; 2019; 25(4):388-395. PubMed ID: 30969164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of NMDA receptors in the treatment of major depression.
    Dang YH; Ma XC; Zhang JC; Ren Q; Wu J; Gao CG; Hashimoto K
    Curr Pharm Des; 2014; 20(32):5151-9. PubMed ID: 24410564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological evidence for glutamatergic pathway involvement in the antidepressant-like effects of 2-phenyl-3-(phenylselanyl)benzofuran in male Swiss mice.
    Rech TDST; Strelow DN; Krüger LD; Neto JSS; Blödorn GB; Alves D; Brüning CA; Bortolatto CF
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Nov; 396(11):3033-3044. PubMed ID: 37160481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disorders.
    Peyrovian B; Rosenblat JD; Pan Z; Iacobucci M; Brietzke E; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():387-404. PubMed ID: 30738126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of calcium, glutamate and NMDA in major depression and therapeutic application.
    Deutschenbaur L; Beck J; Kiyhankhadiv A; Mühlhauser M; Borgwardt S; Walter M; Hasler G; Sollberger D; Lang UE
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():325-33. PubMed ID: 25747801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
    Hillhouse TM; Porter JH
    Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.